Clinical considerations and best practices for safely infusing immunoglobulin in the home setting

Immunoglobulin (Ig) therapies are essential in the treatment of primary immunodeficiency (PID), chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenic purpura (ITP), myasthenia gravis, lupus, rheumatoid arthritis, and other autoimmune disorders. It is pooled with IgG antibodies from thousands of healthy donors and helps reduce the risk of infection and modulates the immune system. 

With the shift toward alternate-site care, research shows that home infusion of Ig therapies has emerged as a safe and effective option—offering clinical outcomes equivalent to in-clinic treatment, with fewer hospitalizations, greater convenience and improved adherence.

Why home infusion makes clinical sense

Home infusion of immunoglobulins offers several key advantages, including:

• Convenience: These are long treatments and can take several hours to administer. Patients can administer their immunoglobulin therapy at home, saving time and avoiding the need for frequent hospital or clinic visits
• Autonomy: With proper training, patients gain control over their treatment, leading to greater independence and confidence in managing their condition. Patients transitioning to subcutaneous infusions can learn and administer this therapy on their own, improving their quality of life. 
• Improved adherence: Home administration increases the likelihood of patients adhering to their prescribed regimen, which is crucial for managing chronic conditions.

Selecting the right product: clinical considerations

Home infusion products include Privigen, Gamunex-C, Gammagard, Hizentra, HyQvia, and Cuvitru, among others. These therapies can be administered intravenously or subcutaneously, with each route offering distinct clinical advantages and considerations. 

Intravenous immunoglobulin (IVIG) allows for higher doses over shorter time frames but requires administration by a healthcare provider, while subcutaneous immunoglobulin (SCIG) offers a slower, more consistent release of IgG, enabling steadier blood levels through frequent self-administered doses without the need for venous access or medical supervision. 

IVIG, typically given every 3 to 4 weeks, can result in peaks and troughs in IgG levels, whereas SCIG maintains more stable levels and is associated with fewer systemic side effects. SCIG offers greater flexibility and independence, making it appealing for individuals with busy schedules. However, factors like needle fear, manual dexterity, and adherence to more frequent dosing must be considered. 

Formulations not only differ in route, but also concentration, sugar stabilizer source (e.g., maltose, glucose), sodium content, osmolality, pH, and IgA levels. These variables should inform clinical decision-making. For example:

• Diabetes: Avoid glucose and maltose-containing products.
• Hypertension or renal impairment: Favor lower sodium and iso-osmolar products.
• IgA deficiency with anti-IgA antibodies: Use low-IgA products to mitigate risk of anaphylaxis.

For a detailed comparison, see theImmunoglobulin Product Booklet from the Immune Deficiency Foundation, which outlines the composition and characteristics of available Ig therapies used in home infusion.

Managing adverse events

Of course, all medications come with side effects.  Infusing immunoglobulin through the IV route may cause common side effects such as headaches, fatigue, fever, chills, nausea, dizziness, rash, and sometimes rare and severe side effects like thrombosis. Patients should be continuously assessed for these side effects, many of which can be mitigated with appropriate interventions. Recommended mitigation strategies include:

• Pre-medication: Administering acetaminophen before the infusion can help reduce fever and headaches.
• Hydration: Fluids before or after the infusion can reduce systemic side effects.
• Infusion rate control: Slowing the infusion rate can help mitigate reactions. Capping the maximum infusion rate to a patient-tolerated rate can be a good strategy.

Subcutaneous immunoglobulin is often administered weekly in the subcutaneous fatty tissue just under the skin. After proper training by nurses, patients are able to self-administer the therapy at home, and while SCIG has less systemic side effects that IVIG, it comes with some common concerns:

Close collaboration with specialty pharmacists, home infusion nurses and care coordinators is essential for reporting and troubleshooting side effects, ensuring that patients can optimize their therapy and successfully continue immunoglobulin infusions at home. By providing personalized guidance and support, these care teams can help patients manage their treatment effectively, reducing the likelihood of complications and improving overall therapy outcomes.

Final Thoughts

Leap offers a robust system for managing immunoglobulin home infusion treatments. With a focus on patient-centered care, Leap’s Care Guides work closely with patients to ensure proper training, continuous monitoring and proactive side effect management. They provide ongoing support, troubleshooting any issues that may arise and ensuring that patients remain confident and comfortable with their treatments.

With Leap's comprehensive support system, patients benefit from a coordinated care team that works together to resolve any issues and optimize treatment outcomes. This collaboration not only ensures safety and efficacy but also enhances the patient’s overall experience by reducing the stress and inconvenience often associated with in-clinic infusions.